When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer

Background: Immune checkpoint inhibitors (ICIs) show clinical benefit in patients with refractory advanced gastric cancer (GC). The ICIs in routine clinical practice have been used in various treatment lines. Therefore, we investigated the timing for application of ICI in patients with refractory ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hongsik, Kim, Hana, Lee, Minsang, Kwon, Minsuk, Hong, Jung Yong, Lee, Jeeyun, Lim, Ho Yeong, Kang, Won Ki, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364657/
https://www.ncbi.nlm.nih.gov/pubmed/34405028
http://dx.doi.org/10.7150/jca.62853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364657/
https://www.ncbi.nlm.nih.gov/pubmed/34405028
http://dx.doi.org/10.7150/jca.62853

Ejemplares similares